12/30/2010

The FDA granted orphan-drug designation to CEQ508, Marina Biotech's lead compound for familial adenomatous polyposis. The status "provides us with significant regulatory and financial incentives to do everything in our power to rapidly move this compound to market," said CEO and President J. Michael French.

Related Summaries